Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein
Open Access
- 3 June 2016
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (11), 1753-1759
- https://doi.org/10.2967/jnumed.115.169078
Abstract
Neuroinflammation is associated with neurodegenerative disease. PET (positron emission tomography) radioligands targeting the 18 kDa translocator protein (TSPO) has been used as in vivo markers of neuroinflammation, but there is an urgent need for novel probes with improved signal-to-noise ratio. Flutriciclamide (18F-GE180) is a recently developed third generation TSPO ligand. In this first study, we evaluated the optimum scan duration and kinetic modelling strategies for 18F-GE180 PET in (older) healthy controls (HC). Methods: Ten HC, six TSPO high affinity binders (HABs) and four mixed affinity binders (MABs), were recruited. All subjects had detailed neuropsychological tests, MRI and a 210 min 18F-GE180 dynamic PET/CT scan using metabolite corrected arterial plasma input function. We evaluated five different kinetic models: irreversible and reversible two-tissue compartment models, a reversible one-tissue model and two models with an extra irreversible vascular compartment. The optimum scan length was investigated based on 210 min scan data. The feasibility of generating parametric maps was also investigated using graphical analysis. Results: 18F-GE180 concentration was higher in plasma than in whole blood during the entire scan duration. Using the kinetic model, the volume of distribution (VT) was 0.17 in HABs and 0.12 in MABs. The model that best represented brain 18F-GE180 kinetics across regions was the reversible two-tissue compartment model (2TCM4k) and 90 min resulted as the optimum scan length required to obtain stable estimates. Logan graphical analysis with arterial input function gave a VT highly consistent with VT in kinetic model, which could be used for voxel-wise analysis. Conclusion: We report for the first time the kinetic properties of the novel third generation TSPO PET ligand, 18F-GE180, in humans: 2TCM4k is the optimal method to quantify the brain uptake, 90 min is the optimal scan length and Logan approach could be used to generate parametric maps. While these control subjects have shown relatively low VT, the methodology presented here forms the basis for quantification for future PET studies using 18F-GE180 in different pathologies.This publication has 23 references indexed in Scilit:
- TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondriaBiochemical Journal, 2016
- The methodology of TSPO imaging with positron emission tomographyBiochemical Society Transactions, 2015
- 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of strokeEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Kinetic Modeling without Accounting for the Vascular Component Impairs the Quantification of [11C]PBR28 Brain PET DataJournal of Cerebral Blood Flow & Metabolism, 2014
- Detection of Microglial Activation in an Acute Model of Neuroinflammation Using PET and Radiotracers11C-(R)-PK11195 and18F-GE-180Journal of Nuclear Medicine, 2014
- The development of an automated and GMP compliant FASTlab™ Synthesis of [18F]GE‐180; a radiotracer for imaging translocator protein (TSPO)Journal of Labelled Compounds and Radiopharmaceuticals, 2013
- Resolution modeling in PET imaging: Theory, practice, benefits, and pitfallsMedical Physics, 2013
- Reactive Astrocytes Overexpress TSPO and Are Detected by TSPO Positron Emission Tomography ImagingJournal of Neuroscience, 2012
- Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseasesInsights into Imaging, 2011
- Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008